How does CHR N's PE Ratio compare to its peers?

CHR N is expensive based on its Price-To-Earnings Ratio (39x) compared to the peer average (24.4x).

How does CHR N's PE Ratio compare vs other companies in the Global Chemicals Industry?

CHR N is expensive based on its Price-To-Earnings Ratio (39x) compared to the Global Chemicals industry average (21.2x).

What is CHR N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHR N is expensive based on its Price-To-Earnings Ratio (39x) compared to the estimated Fair Price-To-Earnings Ratio (14.5x).

What is the Fair Price of CHR N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHR N (MX$1860.86) is trading above our estimate of [[fair value]] (MX$683.67)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

CHR N Stock Overview

CHR N fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	3/6
Financial Health	4/6
Dividends	2/6

Rewards

Earnings are forecast to grow 11.76% per year

Earnings grew by 3.3% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

My Notes

Capture your thoughts, links and company narrative

Chr. Hansen Holding A/S Competitors

CEMEX. de

BMV:CEMEX CPO

Mex$164.3b

Industrias Peñoles. de

BMV:PE&OLES *

Mex$109.8b

Corporación Moctezuma. de

BMV:CMOCTEZ *

Mex$65.0b

GCC. de

BMV:GCC *

Mex$59.0b

Price History & Performance

Summary of share price highs, lows and changes for Chr. Hansen Holding
Historical stock prices
Current Share Price	DKK 1,860.86
52 Week High	DKK 0
52 Week Low	DKK 0
Beta	0.27
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-7.54%

Recent updates

Shareholder Returns

	CHR N	MX Chemicals	MX Market
7D	0%	-3.3%	-4.3%
1Y	0%	-26.2%	-14.1%

Return vs Industry: CHR N exceeded the MX Chemicals industry which returned -14.8% over the past year.

Return vs Market: CHR N underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is CHR N's price volatile compared to industry and market?
CHR N volatility
CHR N Average Weekly Movement	n/a
Chemicals Industry Average Movement	4.8%
Market Average Movement	4.1%
10% most volatile stocks in MX Market	6.0%
10% least volatile stocks in MX Market	2.6%

Stable Share Price: CHR N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CHR N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1843	3,834	Mauricio Graber	www.chr-hansen.com

Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry.

Chr. Hansen Holding A/S Fundamentals Summary

How do Chr. Hansen Holding's earnings and revenue compare to its market cap?
CHR N fundamental statistics
Market cap	Mex$165.57b
Earnings (TTM)	Mex$4.25b
Revenue (TTM)	Mex$24.05b

39.0x

P/E Ratio

6.9x

P/S Ratio

Is CHR N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CHR N income statement (TTM)
Revenue	€1.29b
Cost of Revenue	€585.50m
Gross Profit	€708.00m
Other Expenses	€479.40m
Earnings	€228.60m

Last Reported Earnings

Feb 28, 2023

Next Earnings Date

Jul 06, 2023

Earnings per share (EPS)	1.74
Gross Margin	54.74%
Net Profit Margin	17.67%
Debt/Equity Ratio	58.1%

How did CHR N perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

55%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/06/13 12:45
End of Day Share Price	2023/03/16 00:00
Earnings	2023/02/28
Annual Earnings	2022/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chr. Hansen Holding A/S is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Vitfell-Rasmussen	ABG Sundal Collier
Alexander Sloane	Barclays
James Targett	Berenberg

This company is no longer active

CHR N Stock Overview

Rewards

Risk Analysis

Chr. Hansen Holding A/S Competitors

BMV:CEMEX CPO

Mex$164.3b

BMV:PE&OLES *

Mex$109.8b

BMV:CMOCTEZ *

Mex$65.0b

BMV:GCC *

Mex$59.0b

Price History & Performance

Recent News & Updates

Chr. Hansen Holding A/S(CPSE:CHR) dropped from FTSE All-World Index (USD)

Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Copenhagen 20 Index

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Chr. Hansen Holding A/S to Report Fiscal Year 2024 Results on Feb 06, 2025

Chr. Hansen Holding A/S Revises Revenue Guidance for January 1, 2023 – December 31, 2023

Recent updates

Chr. Hansen Holding A/S(CPSE:CHR) dropped from FTSE All-World Index (USD)

Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Copenhagen 20 Index

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Chr. Hansen Holding A/S to Report Fiscal Year 2024 Results on Feb 06, 2025

Chr. Hansen Holding A/S Revises Revenue Guidance for January 1, 2023 – December 31, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Chr. Hansen Holding A/S Provides Earnings Guidance for the Period September 1, 2022 – August 31, 2023

Executive VP recently bought Mex$1.5m worth of stock

First quarter 2023 earnings released: EPS: €0.38 (vs €0.35 in 1Q 2022)

Chr. Hansen Holding A/S Provides Revenue Guidance for 2022/23

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Key Executive recently bought Mex$135k worth of stock

Chr. Hansen Holding A/S Approves Ordinary Dividend

Upcoming dividend of kr.7.04 per share

High number of new directors

Chr. Hansen Holding A/S to Report Q1, 2023 Results on Dec 12, 2022

Full year 2022 earnings released: EPS: €1.71 (vs €1.51 in FY 2021)

Chr. Hansen Holding A/S Proposes Ordinary Dividend for 2021/22

High number of new directors

Chr. Hansen Holding A/S to Report Q2, 2023 Results on Apr 13, 2023

Third quarter 2022 earnings released: EPS: €0.45 (vs €0.38 in 3Q 2021)

Chr. Hansen Holding A/S Provides Earnings Guidance for the Full Year of Fiscal 2022

High number of new directors

Shareholder Returns

Price Volatility

About the Company

Chr. Hansen Holding A/S Fundamentals Summary

39.0x

6.9x

Earnings & Revenue

Dividends

1.4%

55%

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources